Coloplast A/S (OTCMKTS:CLPBY) Upgraded by Sanford C. Bernstein to “Strong-Buy” Rating

Coloplast A/S (OTCMKTS:CLPBY) was upgraded by investment analysts at Sanford C. Bernstein from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Several other equities analysts have also issued reports on the company. UBS Group raised Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 11th. Hsbc Global Res raised Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research report on Monday, November 18th.

Coloplast A/S Stock Performance

Shares of Coloplast A/S stock opened at $11.59 on Tuesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.02 and a quick ratio of 0.66. The business has a fifty day simple moving average of $11.54 and a two-hundred day simple moving average of $12.61. Coloplast A/S has a 12 month low of $10.63 and a 12 month high of $14.34.

Coloplast A/S (OTCMKTS:CLPBY) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter. The firm had revenue of $1.02 billion during the quarter. Coloplast A/S had a return on equity of 30.19% and a net margin of 18.69%. On average, research analysts expect that Coloplast A/S will post 0.36 earnings per share for the current year.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.